FAKTOR-ZERTIFIKAT - TANDEM DIABETES CARE Stock

Certificat

DE000JK78CW1

Market Closed - Börse Stuttgart 03:42:35 2024-07-02 pm EDT
7.17 EUR -5.91% Intraday chart for FAKTOR-ZERTIFIKAT - TANDEM DIABETES CARE
Current month-17.59%
1 month-63.92%
Date Price Change
24-07-02 7.17 -5.91%
24-07-01 7.62 -12.41%
24-06-28 8.7 +6.88%
24-06-27 8.14 -0.97%
24-06-26 8.22 +5.12%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 03:42 pm EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying TANDEM DIABETES CARE, INC.
Issuer J.P. Morgan
WKN JK78CW
ISINDE000JK78CW1
Date issued 2024-05-06
Strike 26.11 $
Maturity Unlimited
Parity 1.76 : 1
Emission price 10.08
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 19.87
Lowest since issue 7.17
Spread 0.5
Spread %6.48%

Company Profile

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company, which manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of it AID systems, it offers pump integration with multiple CGM sensors.
Sector
-
More about the company

Consensus: Tandem Diabetes Care, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
39.15 USD
Average target price
49.93 USD
Spread / Average Target
+27.54%
Consensus